The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Samsung Bioepis
Stock and Other Ownership Interests - Samsung Biologics
 
Research Funding - Samsung Bioepis
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
 
Xavier B. Pivot
Consulting or Advisory Role - Samsung Bioepis
 
Igor Bondarenko
No Relationships to Disclose
 
Mikhail Dvorkin
No Relationships to Disclose
 
Ekaterina Trishkina
No Relationships to Disclose
 
Jin-Hee Ahn
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Hanmi; Novartis; Spectrum Pharmaceuticals
 
Tomasz Sarosiek
No Relationships to Disclose
 
Sanjay Chattopadhyay
No Relationships to Disclose
 
Marek Wojtukiewicz
No Relationships to Disclose
 
Vladimir Moiseyenko
No Relationships to Disclose
 
Yaroslav V. Shparyk
No Relationships to Disclose
 
Maximino De Guzman Bello
Research Funding - Eisai
 
Vladimir Semiglazov
No Relationships to Disclose
 
Sujeong Song
Employment - Samsung Bioepis
Stock and Other Ownership Interests - Samsung Biologics
 
Jae Yun Lim
No Relationships to Disclose